Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical [Read more]